Clinical Focus
Business Focus
Spotlight
Subscribe
CE/CME
- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
Panelists discuss how teplizumab binds to T cells and modifies their function to preserve beta cell function, potentially delaying type 1 diabetes onset in at-risk individuals by an average of 2-3 years.
EP: 1.Assessing the Burden of Type 1 Diabetes
EP: 2.Guidelines for Type 1 Diabetes Screening
EP: 3.Defining the Stages of Type 1 Diabetes
EP: 4.Impact of Delayed Intervention In Stage 2 Type 1 Diabetes
EP: 5.Screening for Autoantibodies in Type 1 Diabetes
Now Viewing
EP: 6.Mechanism of Action of Teplizumab in Delaying Onset and Progression of Type 1
EP: 7.Clinical Trial Data for Teplizumab
EP: 8.Patient Selection for Teplizumab and Infusion Process
Related Videos
Related Content
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
October 27th 2025Article
After 1 year of coaching by the AI app or a DPP-associated coach, reductions in weight and HbA1c and increases in physical activity were equal, an outcome with great promise for scalability.
